AstraZeneca And Daiichi Sankyo Report DESTINY‑Lung04 Phase III Trial Results; ENHERTU Improves Progression‑Free Survival Versus Standard Of Care In HER2‑Mutant NSCLC
AstraZeneca and Daiichi Sankyo’s ENHERTU is the first and only HER2-directed medicine to improve progression-free survival over global standard of care in a Phase III trial in this settingPositive high-level results
AstraZeneca's cancer medicine ENHERTU worked better than the usual treatment in a big test, helping patients live longer without their cancer getting worse. This is good news because it shows the medicine does what doctors hoped, which can make people trust the company more.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.